查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970958

皮膚癌治療市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病類型、治療方法、地區和競爭格局分類，2021-2031年

Skin Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球皮膚癌治療市場預計將從 2025 年的 68.9 億美元成長到 2031 年的 105.1 億美元，複合年成長率為 7.29%。

該市場涵蓋多種藥物療法，例如化療、標靶治療和免疫療法，用於治療包括鱗狀細胞癌、基底細胞癌和惡性黑色素瘤在內的惡性腫瘤。市場成長的主要驅動力是全球皮膚癌發生率的上升，這歸因於人口老化和紫外線照射的增加。此外，診斷技術的進步使得疾病能夠更早被發現，從而導致需要即時持續治療的患者數量顯著增加。

市場概覽
預測期 2027-2031
市場規模：2025年 68.9億美元
市場規模：2031年 105.1億美元
複合年成長率：2026-2031年 7.29%
成長最快的細分市場 免疫療法
最大的市場 北美洲

儘管有這些成長要素，但先進生物療法的高昂成本常常阻礙市場擴張。這些成本限制了病患的就醫途徑，並加重了價格敏感地區的醫療預算負擔。儘管疾病負擔日益加重，但這一經濟障礙仍然是新治療方法廣泛應用的主要阻礙。例如，美國癌症協會估計，到2024年，美國將新增約100,640例侵襲性黑色素瘤病例，凸顯了迫切需要有效的治療方案來應對這一日益嚴峻的健康挑戰。

市場促進因素

全球黑色素瘤和非黑色素瘤皮膚癌發生率的不斷上升是推動全球皮膚癌治療市場發展的主要動力。隨著全球人口老化和紫外線輻射環境暴露的增加，診斷率持續上升，對穩定有效的藥物治療的需求也日益成長。患者負擔的加重直接導致現有療法的銷售增加，同時也為新參與企業創造了市場機會。根據美國癌症協會發布的《2024年癌症事實與數據》，預計2024年美國將有約8,290人死於黑色素瘤，凸顯了該疾病的高致死率以及延長患者生存期所需的強效治療方案。

標靶藥物遞送技術和免疫療法的快速發展推動了這一日益成長的需求。這些技術將治療重點從安寧療護轉向根治性治療，從而增強了市場提案。該領域的創新技術在後期臨床試驗中展現出顯著成果，改善了臨床療效，並支撐了高額定價，從而實現了高利潤。例如，默克在2024年2月報告稱，受轉移性疾病（包括黑色素瘤）領域強勁需求的推動，Keytruda在2023年的全球銷售額成長了19%，達到250億美元。此外，監管機構也對這些創新持正面態度。 2024年，Iovance Biotherapeutics宣布，FDA已加速核准Amtagvi上市，是第一個用於治療固體癌腫瘤的細胞療法。

市場挑戰

先進生物治療方法（包括免疫療法和標靶治療）的高昂成本是全球皮膚癌治療市場成長的主要障礙。儘管這些治療方法能夠改善惡性腫瘤的臨床療效，但其高昂的價格對醫療預算造成壓力，並限制了健保報銷，尤其是在價格敏感地區。因此，嚴格的保險覆蓋標準和高額的自付費用往往限制了患者獲得這些治療的機會。這種經濟負擔降低了新治療方法的普及率，抑制了銷售量，並阻礙了市場充分利用日益成長的有效皮膚癌治療需求。

這種經濟障礙造成了治療方法與急需治療的患者之間的差距，阻礙了市場有效減輕疾病負擔的能力。目前，由於無法獲得最佳治療，死亡率居高不下，凸顯了這個限制因素。根據美國癌症協會估計，到2025年，美國將有約8,430人死於黑色素瘤。這項統計數據表明，高昂的治療費用限制了救命治療的提供，從而造成了巨大的臨床缺口，最終限制了收入潛力和全球市場擴張。

市場趨勢

隨著個人化mRNA癌症疫苗的商業化進程不斷推進，治療策略正發生顯著轉變，從現成的免疫療法轉向個人化新抗原療法。這些治療方法利用mRNA編碼患者特異性突變，活化免疫系統，比單獨使用抑制劑更有效清除癌細胞。近期數據顯示，這些療法具有生存優勢，也支持了這項轉變。默克在2024年6月發布的題為「Moderna和默克公佈三年數據」的新聞稿中指出，在高危險群Pembrolizumab患者中，與Pembrolizumab單藥聯合治療相比，mRNA-4157試驗性疫苗合併帕博利珠單抗治療可使復發或死亡風險降低49%。

同時，對於可切除的黑色素瘤，新輔助免疫療法正逐漸興起，治療時機提前至術前。透過在術前使用雙重查核點抑制劑，可以刺激腫瘤，誘導強烈的T細胞反應。與術後治療通訊協定相比，這顯著改善了治療效果，同時也使臨床醫生能夠評估病理反應。根據2024年6月在歐洲腫瘤內科學會（ESMO）年會上發表的數據，III期NADINA試驗證實了該方法的有效性，新輔助輔助性治療組的12個月無惡化存活期為83.7%，而術後輔助性治療組為57.2%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球皮膚癌治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 疾病類型（惡性黑色素瘤、非惡性黑色素瘤）
    • 治療方法（化療、免疫療法、標靶治療、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美皮膚癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲皮膚癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區皮膚癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲皮膚癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲皮膚癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球皮膚癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline PLC
  • Pfizer Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23980

The Global Skin Cancer Therapeutics Market is projected to expand from USD 6.89 Billion in 2025 to USD 10.51 Billion by 2031, reflecting a compound annual growth rate of 7.29%. This market encompasses various pharmaceutical interventions, such as chemotherapy, targeted therapy, and immunotherapy, designed to treat malignancies including squamous cell carcinoma, basal cell carcinoma, and melanoma. The market's growth is primarily fueled by the increasing global incidence of skin cancer, driven by an aging population and heightened exposure to ultraviolet radiation. Additionally, advancements in diagnostic capabilities have facilitated earlier disease detection, significantly enlarging the patient population that requires immediate and sustained therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.89 Billion
Market Size 2031USD 10.51 Billion
CAGR 2026-20317.29%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Despite these growth drivers, market expansion is frequently hindered by the prohibitive costs of advanced biologic treatments, which restrict patient access and place a strain on healthcare budgets in price-sensitive regions. This financial barrier poses a substantial obstacle to the widespread adoption of newer therapies, even as the burden of disease increases. For instance, the American Cancer Society estimated that in 2024, approximately 100,640 new cases of invasive melanoma were diagnosed in the United States, highlighting the critical and urgent need for effective therapeutic solutions to address this growing health challenge.

Market Driver

The escalating global prevalence of melanoma and non-melanoma skin cancers acts as the fundamental driver for the Global Skin Cancer Therapeutics Market. As the global population ages and environmental exposure to ultraviolet radiation intensifies, diagnosis rates continue to rise, creating a need for a consistent supply of effective pharmaceutical interventions. This increasing patient burden leads directly to higher sales volumes for existing treatments and opens the market for new entrants. According to the American Cancer Society's 'Cancer Facts & Figures 2024', approximately 8,290 deaths from melanoma were projected to occur in the United States in 2024, underscoring the lethal nature of the disease and the imperative for potent therapeutic options that extend patient survival.

Complementing this volume-driven growth is the rapid advancement in targeted drug delivery and immunotherapy, which enhances the market's value proposition by shifting focus from palliative care to curative intent. Innovations in this sector have demonstrated remarkable success in late-stage trials, improving clinical outcomes and justifying premium pricing structures that bolster overall revenue. For example, Merck & Co. reported in February 2024 that worldwide sales of Keytruda increased by 19% to $25.0 billion in 2023, driven by strong demand in metastatic indications including melanoma. Furthermore, regulatory bodies are accommodating these innovations; in 2024, Iovance Biotherapeutics announced that the FDA granted accelerated approval for Amtagvi, the first cellular therapy indicated for a solid tumor malignancy.

Market Challenge

The substantial cost of advanced biologic treatments, including immunotherapies and targeted therapies, acts as a significant impediment to the growth of the Global Skin Cancer Therapeutics Market. While these interventions offer improved clinical outcomes for malignancies, they command premium prices that strain healthcare budgets and limit reimbursement coverage, particularly in regions sensitive to price. Consequently, strict insurance approval criteria and high out-of-pocket expenses often restrict patient access to these medications. This financial toxicity lowers adoption rates for newer therapies, thereby limiting sales volume and preventing the market from fully capitalizing on the rising demand for effective skin cancer management.

This economic barrier creates a disconnect between the availability of treatments and the patients who urgently require them, hampering the market's ability to effectively address the disease burden. The persistence of mortality rates, driven in part by limited access to optimal care, highlights this constraint. According to the American Cancer Society, an estimated 8,430 deaths are expected to be attributed to melanoma in the United States in 2025. This statistic underscores a significant clinical gap where the high cost of therapy restricts the delivery of life-saving care, ultimately constraining the revenue potential and expansion of the global market.

Market Trends

The increasing commercialization of personalized mRNA cancer vaccines marks a pivotal advancement, shifting from off-the-shelf immunotherapies to individualized neoantigen strategies. These therapies utilize mRNA to encode patient-specific mutations, priming the immune system to eliminate cancer cells more effectively than inhibitors alone, a shift supported by recent data showing superior survival rates. According to Merck & Co., in June 2024, the investigational vaccine mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% compared to pembrolizumab monotherapy in high-risk melanoma patients, as reported in their 'Moderna & Merck Announce 3-Year Data' release.

Simultaneously, the market is moving toward neoadjuvant immunotherapy for resectable melanoma, changing the timing of intervention to the preoperative setting. Administering dual checkpoint blockade before surgery leverages the tumor to generate a robust T-cell response, significantly improving outcomes compared to postoperative protocols while allowing clinicians to assess pathological response. According to the European Society for Medical Oncology in June 2024, the Phase 3 NADINA trial showed a 12-month event-free survival rate of 83.7% in the neoadjuvant group versus 57.2% for the adjuvant cohort, demonstrating the efficacy of this approach.

Key Market Players

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline PLC
  • Pfizer Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.

Report Scope

In this report, the Global Skin Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Skin Cancer Therapeutics Market, By Disease Type

  • Melanoma
  • Non-melanoma

Skin Cancer Therapeutics Market, By Treatment

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Others

Skin Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Skin Cancer Therapeutics Market.

Available Customizations:

Global Skin Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Skin Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Melanoma, Non-melanoma)
    • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Skin Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Treatment
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Skin Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Skin Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Skin Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Treatment

7. Europe Skin Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Treatment
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Skin Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Treatment
    • 7.3.2. France Skin Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Skin Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Skin Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Skin Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Treatment

8. Asia Pacific Skin Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Skin Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Treatment
    • 8.3.2. India Skin Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Treatment
    • 8.3.3. Japan Skin Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Skin Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Skin Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Treatment

9. Middle East & Africa Skin Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Treatment
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Skin Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Treatment
    • 9.3.2. UAE Skin Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Treatment
    • 9.3.3. South Africa Skin Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Treatment

10. South America Skin Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Treatment
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Skin Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Colombia Skin Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Treatment
    • 10.3.3. Argentina Skin Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Skin Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Company
  • 15.3. Merck & Co., Inc.
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Sanofi SA
  • 15.6. F. Hoffmann-La Roche Ltd.
  • 15.7. Glaxosmithkline PLC
  • 15.8. Pfizer Inc.
  • 15.9. Novartis AG
  • 15.10. Regeneron Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer